They are essentially based on the deregulation of the anti-apoptotic gene BCL2, mimicking the founder t(14;18) translocation common to the pathogenesis of FL and GCB-DLBCL, and a second hit affecting GC B cell differentiation (68). Here, BCL2 is linked to diffuse large B-cell lymphoma.